PT - JOURNAL ARTICLE AU - Waszczuk, Monika A. AU - Morozova, Olga AU - Lhuillier, Elizabeth AU - Docherty, Anna R. AU - Shabalin, Andrey A. AU - Yang, Xiaohua AU - Carr, Melissa A. AU - Clouston, Sean A. P. AU - Kotov, Roman AU - Luft, Benjamin J. TI - Polygenic Risk Scores for Asthma and Allergic Disease Predict COVID-19 Severity in 9/11 Responders AID - 10.1101/2022.08.30.22279383 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.30.22279383 4099 - http://medrxiv.org/content/early/2022/08/30/2022.08.30.22279383.short 4100 - http://medrxiv.org/content/early/2022/08/30/2022.08.30.22279383.full AB - Background Genetic factors contribute to individual differences in the severity of coronavirus disease 2019 (COVID-19). A portion of genetic predisposition can be captured using polygenic risk scores (PRS). Relatively little is known about the associations between PRS and COVID-19 severity or post-acute COVID-19 in community-dwelling individuals.Methods Participants in this study were 983 World Trade Center responders infected for the first time with SARS-CoV-2 (mean age at infection=56.06, standard deviation [SD]=7.37, 918 (93.4%) male, 813 (82.7%) European ancestry). Seventy-five (7.6%) responders were in the severe COVID-19 category, that included hospitalization and other adverse outcomes; 306 (31.1%) reported at least one post-acute COVID-19 symptom at the 4-week follow-up. Analyses were adjusted for population stratification and demographic covariates.Findings In responders with European ancestry, the asthma PRS was associated with severe COVID-19 category (odds ratio [OR]=1.61, 95% confidence interval: 1.17-2.21) and more severe COVID-19 symptomatology (β=.09, p=.01), independently of respiratory disease diagnosis. The allergic disease PRS similarly associated with severe COVID-19 category (OR=1.97, [1.26-3.07]). The PRS for COVID-19 hospitalization was associated with the risk of severe COVID-19 category (OR=1.35, [1.01-1.82]), but this association was smaller than for the asthma PRS. PRS for coronary artery disease and type II diabetes were not associated with COVID-19 severity.Interpretation Taken together, the results indicate that recently developed polygenic biomarkers for asthma, allergic disease, and COVID-19 hospitalization capture some of the individual differences in severity and clinical course of COVID-19 illness in a community population.Funding National Institute for Occupational Safety and Health, CDC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by CDC/NIOSH awards U01OH012275 to Drs. Luft and Morozova, and U01OH011864 to Drs. Waszczuk and Kotov. Additional support was provided by National Institute of Health awards R01MH123619 and R01MH123489 to Drs. Docherty and Shabalin. We would like to acknowledge ongoing funding to monitor World Trade Center responders as part of the WTC Health and Wellness Program (CDC 200-2011-39361). We thank participants for their commitment to the project. The findings and conclusions in this article are those of the authors and do not represent the official position of CDC. The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Reviewer Board of Stony Brook UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMedical information is protected, so only processed de-identified data will be made available upon receipt of a written request to the corresponding author after the manuscript publication.